Development of a Human Preclinical Platform for the Identification of Neuroprotective Compounds.

ABSTRACT: Multiple sclerosis (MS) is the most common inflammatory and demyelinating disease affecting the central nervous system (CNS). While immune-modulating drugs can prevent new lesions by targeting lymphocyte activity, treating relapse-independent disease progression remains challenging. Persisting CNS inflammation, leading to axonal and neuronal injury along with failure of compensatory mechanisms, such as brain plasticity and remyelination, drives disease progression. Thus, identifying neuroprotective and/or remyelination-promoting compounds is urgently needed. We developed an in vitro platform utilizing human-induced pluripotent stem cell (iPSC)-derived neurons and oligodendrocytes to assess neuroprotective and potentially promyelinating effects of selected compounds. We established assays m

SUBMITTER: Gonzalez RG 

PROVIDER: S-EPMC12641211 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature